Bevacizumab Doubles the Early Postoperative Complication Rate after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis of Colorectal Origin

2013/12/14 by Clarisse Eveno, Guillaume Passot, Diane Goéré +9 · 2 citations
Medicine · #Adrenal and Paraganglionic Tumors #Intraperitoneal and Appendiceal Malignancies #Occupational and environmental lung diseases

paper · doi:10.1245/s10434-013-3442-3

openalex publication_date 2013/12/14 · crossref created 2013/12/14 · crossref issued 2013/12/15 · crossref published 2013/12/15 · crossref published-online 2013/12/15 · crossref published-print 2014/06/01 · crossref deposited 2019/06/04 · openalex created_date 2025/10/10 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/30

Citations

• Classification of Surgical Complications
• Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples
• The central role of the propensity score in observational studies for causal effects

Cited by

• Neoadjuvant Chemotherapy with Bevacizumab May Improve Outcome after Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Colorectal Carcinomatosis
• Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy